^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
MHB088C
i
Other names: MHB088C, MHB 088C, MHB-088C, QLC5508
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Minghui Pharma, Qilu Pharma
Drug class:
Topoisomerase I inhibitor, B7-H3-targeted antibody-drug conjugate
Related drugs:
2d
QLC5508 in Participants With Metastatic Prostate Cancer (clinicaltrials.gov)
P3, N=700, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
New P3 trial
|
docetaxel • MHB088C
8d
QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction (clinicaltrials.gov)
P1, N=48, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
New P1 trial
|
Nubeqa (darolutamide) • itraconazole • MHB088C • rifampicin
8d
A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer (clinicaltrials.gov)
P1/2, N=212, Recruiting, Qilu Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
enzalutamide • abiraterone acetate • MHB088C
2ms
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
P3, N=466, Recruiting, Qilu Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
paclitaxel • docetaxel • irinotecan • MHB088C
3ms
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
P3, N=466, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
New P3 trial
|
paclitaxel • docetaxel • irinotecan • MHB088C
6ms
QLC5508-201: A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=444, Recruiting, Qilu Pharmaceutical Co., Ltd.
New P1/2 trial
|
cisplatin • carboplatin • paclitaxel • 5-fluorouracil • oxaliplatin • Qibeian (iparomlimab/tuvonralimab) • MHB088C
7ms
A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1/2, N=116, Recruiting, Minghui Pharmaceutical (Hangzhou) Ltd
New P1/2 trial
|
MHB088C
7ms
An open-label, multicenter Phase Ib/II clinical study on the safety, tolerability, pharmacokinetics, and efficacy of QLC5508 injection combined therapy in patients with advanced solid tumors (ChiCTR2500110587)
P1/2, N=414, Not yet recruiting, Shanghai East Hospital; Qilu Pharmaceutical Co.
New P1/2 trial
|
cisplatin • carboplatin • paclitaxel • 5-fluorouracil • oxaliplatin • Qibeian (iparomlimab/tuvonralimab) • MHB088C • levoleucovorin calcium
8ms
A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer (clinicaltrials.gov)
P1/2, N=212, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
New P1/2 trial
|
enzalutamide • abiraterone acetate • MHB088C
10ms
Study of MHB088C for Patients With Advanced Solid Malignant Tumors (clinicaltrials.gov)
P1/2, N=515, Recruiting, Qilu Pharmaceutical Co., Ltd.
New P1/2 trial
|
MHB088C
12ms
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
P3, N=450, Recruiting, Qilu Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
paclitaxel • irinotecan • topotecan • MHB088C
1year
Phase III study of MHB088C comparing physicians' treatment of choice in recurrent small cell lung cancer (ChiCTR2500101326)
P3, N=450, Not yet recruiting, Shanghai East Hospital; Shanghai East Hospital
New P3 trial
|
CD276 (CD276 Molecule)
|
paclitaxel • topotecan • MHB088C
Share via
